Scripps Research & Bridge Biotherapeutics form two-year collaboration
Category: #health  By Pankaj Singh  Date: 2022-02-09
 | 
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Scripps Research & Bridge Biotherapeutics form two-year collaboration

Bridge Biotherapeutics Inc. and Scripps Research have reportedly formed a two-year research partnership to discover and identify the advanced reactive group that focuses non-cysteine residues to unravel new druggable sites in high-value therapeutic targets.

Under the multi-year partnership agreement, Scripps will perform research and development activities whereas Bridge Biotherapeutics will maintain an exclusive alternative to acquire global patent and license rights from the research program to further develop and promote the technology.

Bridge Biotherapeutics will partner with Benjamin F. Cravatt III, Ph.D., and Phil S. Baran, Ph.D., pioneers in chemical biology and covalent targeting. The company intends to develop advanced therapeutics for high-value targets in the immunology and oncology space. It believes that advanced reactive group chemistries in combination with proteomics can help in attaining this objective. Bridge looks to explore tunable, proprietary ligands for protein degrader applications and the development of covalent drugs.

Dr. Cravatt and Dr. Baran will be the lead investigators on the project. Dr. Baran is hoping to characterize and validate new targeting axes in the immunology and oncology space and eventually provide advanced life-altering therapies.

According to the Executive Vice President of Bridge Biotherapeutics B. Christopher Kim, Ph.D., the research partnership with Scripps Research paves a new way to the activities of drug discovery and development focused on oncogenic mutations.

Kim added that the company intends to develop a tunable and advanced platform to develop highly selective compounds to acknowledge unmet requirements in multiple disease states.

For those unversed, Bridge Biotherapeutics is a publicly-traded biotech firm headquartered in the Republic of Korea with offices in China, and the United States. The company focuses on the discovery and development of advanced therapeutics for disease indications with high unfulfilled medical needs in ulcerative colitis, cancer, and fibrotic diseases.

Some of the products in the company’s pipeline include BBT-877, an advanced autotaxin inhibitor for treating fibrotic diseases like IPF (idiopathic pulmonary fibrosis), BBT-401, a Pellino-1 inhibitor for treating ulcerative colitis, and BBT-176, an effective targeted cancer therapy for NSCLC (non-small cell lung cancer).

Source credit:

https://www.prnewswire.com/news-releases/bridge-biotherapeutics-and-scripps-research-launch-research-collaboration-to-develop-discovery-platform-and-novel-covalent-probes-based-on-chemical-biology-and-chemoproteomics-301475490.html



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

By Pankaj Singh

Rona Therapeutics Inc has reportedly acquired the global exclusive rights to the siRNA platform of delivery moiety and chemical modification from Sanofi S.A., in addition to four pre-clinical contenders for unrevealed ...

Toy maker Mattel inks multi-year agreement with Elon Musk’s SpaceX

Toy maker Mattel inks multi-year agreement with Elon Musk’s SpaceX

By Pankaj Singh

California-based toy manufacturing and entertainment company, Mattel, has recently signed a multi-year agreement with Elon Musk’s private spaceflight company, SpaceX.

T...

USHV partners with Willowbrook to provide quality cardiovascular care

USHV partners with Willowbrook to provide quality cardiovascular care

By Pankaj Singh

US Heart & Vascular (USHV) is reportedly partnering with Willowbrook Cardiovascular Associates to offer quality cardiovascular care in the Houston market.

USHV has a strong ma...